Key literature

Protein Mimicry & CLIPS technology:

  1. Timmerman P, Barderas R, Desmet J, Altschuh D, Shochat S, Hollestelle MJ,Höppener JWM, Monasterio A, Casal JI, Meloen RH. Binding of CDR-derived peptidomimetics is mechanistically different from that of high-affinity parental antibodies. J. Mol. Recognit. 2010, 23, 559-568.  
  2. Timmerman P, Puijk WC, Boshuizen RS, van Dijken P, Slootstra JW, Beurskens FJ, Parren PWHI, Huber A, Bachmann MF, Meloen RH. Functional reconstruction of structurally complex epitopes using CLIPS® technology. Open Vaccine J.2009, 2, 56-67.  
  3. Timmerman P, Barderas R, Desmet J, Altschuh D, Shochat S, Hollestelle MJ, Höppener JWM, Monasterio A, Casal JI, Meloen RH. A combinatorial approach for the design of complementarity determining regions (CDR)-derived peptidomimetics with anti-tumoral activity. J. Biol. Chem. 2009, 284, 34126-34134.
  4. Timmerman P, Puijk WC, Meloen RH. Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS®technology.J. Mol. Recognit. 2007, 20, 283-299.  
  5. Timmerman P, Beld J, Puijk WC, Meloen RH. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chembiochem. 2005, 6, 821-824. 
  6. Ferrat G, Renisio JG, Morelli X, Slootstra J, Meloen RH, Cambillau C, Darbon H. A peptide mimic of an antigenic loop of alpha-human chorionic gonadotropin hormone: solution structure and interaction with a llama V(HH) domain. Biochem. J. 2002, 366, 415-422. 
  7. Villén J, Borràs E, Schaaper WM, Meloen RH, Dávila M, Domingo E, Giralt E, Andreu D. Functional mimicry of a discontinuous antigenic site by a designed synthetic peptide. Chembiochem. 2002, 3, 175-182. 
  8. Villén J, Borràs E, Schaaper WM, Meloen RH, Dávila M, Domingo E, Giralt E, Andreu D. Synthetic peptides as functional mimics of a viral discontinuous antigenic site. Biologicals 2001, 29, 265-9. 
  9. Schaaper WMM, Posthuma GA, Plasman HH, Sijtsma L, Fant F, Borremans FAM, Thevissen K, Broekaert WF, Meloen RH, Van Amerongen A. Synthetic peptides derived from the ß2-ß3 loop of Raphanus sativus antifungal protein 2 that mimic the active site. J. Pept. Res. 2001, 57, 409-418.
  10. Zijlstra-Westhoff WE, Slootstra JW, Puijk WC, Schaaper WMM, Oonk HB, Meloen RH. In vitro inhibition of the bioactivity of follicle-stimulating hormone by antisera against a peptide representing part of the FSH receptor.  J. Reprod. Immunol. 1998, 38, 139-154.
  11. Westhoff WE, Slootstra JW, Puijk WC, Schaaper WMM, Oonk HB, Meloen RH. In vitro inhibition of the biological action of follicle stimulating hormone by anti-peptide antisera representing the human follicle stimulating hormone beta subunit sequence 33-53. Biol. Reprod. 1997, 56, 460-468.

Epitope Mapping & CLIPS technology:

  1. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke A, Wiegmann K, Jenewein S, Slootstra JW, Timmerman P, Brännström A, Lindstrom F, Mössner E, Umana P, Hopfner K-P, Klein C. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011, in press.
  2. Tauriello DVF, Kirchner K, Slootstra JW, Jordens I, Kruitwagen T, Bouwman B, Noutsou M, Rüdiger S, Schwamborn K, Schambony A, Maurice MM. Dvl1 employs its DEP-domain and C-terminus to bind a discontinuous motif in the Fz5-receptor and initiate Wnt/b-catenin signaling, manuscript submitted for publication.
  3. Langedijk JP, Zekveld MJ, Ruiter M, Back JW. Large helical peptide libraries for lead finding and interaction site mapping. Manuscript submitted for publication in Analytical Biochemistry. 
  4. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5.
  5. Schwamborn K, Knipscheer P, van Dijk E, van Dijk WJ, Sixma TK, Meloen RH, Langedijk JP. SUMO assay with peptide arrays on solid support: insights into SUMO target sites. J. Biochem. 2008, 144, 39-49.
  6. Hollestelle MJ, Timmerman P, Meloen RH, Höppener JWM. Characterization of Gastrin-cholecystokinin2-receptor interaction in relation to c-fos induction. Endocr. Relat. Canc. 2008, 15, 301-309.
  7. Teeling JL, Mackus WJM, Wiegman LJJM, Van den Brakel JHN, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PWHI, Glennie MJ, van de Winkel JGJ. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 171, 362–371.
  8. Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J. Virol. 2005, 79, 4672-8.
  9. Bernard J, Harb C, Mortier E, Quéméner A, Meloen RH, Vermot-Desroches C, Wijdeness J, van Dijken P, Grötzinger J, Slootstra JW, Plet A, Jacques Y. Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. J. Biol. Chem. 2004, 279, 24313-24322.
  10. Timmerman P, van Dijk E, Puijk W, Schaaper W, Slootstra JW, Carlisle SJ, Coley J, Eida S, Gani M., Hunt T, Perry P, Piron G, Meloen RH. Mapping of a discontinuous and highly conformational binding site on follicle stimulating hormone subunit-ß (FSH-ß) using domain scan and matrix scan technology. Mol. Divers. 2004, 8, 61-77.
  11. Langeveld JPM, Martinez-Torrecuadrada J, Boshuizen RS, Meloen RH, Casal JI. Characterization of a protective linear B cell epitope against feline parvoviruses. Vaccine 2001, 19, 2352-2360.
  12. Dionyssopoulou H, Mouzaki A, Slootstra J, Puijk W, Meloen RH, Cordopatis P, Sotiropoulou G. Synthetic peptides as putative agents in transplantation medicine: application of PEPSCAN to the identification of functional sequences in the extracellular domain of the interleukin-2 receptor beta chain (IL-2Rb).  J. Immunol. Methods 2000, 241, 83-95.
  13. Meloen RH, Puijk WC, Slootstra JW. Mimotopes: realization of an unlikely concept. J. Mol. Recognit. 2000, 13, 352-359.
  14. Kamstrup S, Langeveld J, Bøtner A, Nielsen J, Schaaper WMM, Boshuizen RS, Casal JI, Højrup P, Vela C, Meloen RH, Dalsgaard K. Mapping the antigenic stucture of porcine parvovirus at the level of peptides. Virus Res. 1998, 53, 163-173.
  15. Williams SC, Badley RA, Davis PJ, Puijk WC, Meloen RH, Oirschot JT. Identification of epitopes within beta lactoglobulin recognized by polyclonal antibodies using phage display and PEPSCAN. J. Immunol. Methods 1998, 213, 1-17.
  16. Slootstra JW, Puijk WC, Ligtvoet GJ, Kuperus D, Schaaper WMM, Meloen RH. Screening of a small set of random peptides: A new strategy to identify synthetic peptides that mimic epitopes. J. Mol. Recogn. 1997, 10, 217-224.
  17. Slootstra JW, Puijk WC, Ligtvoet GJ, Langeveld JPM, Meloen RH. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol. Divers. 1996, 1, 87-96.
  18. Westhoff WE, Slootstra JW, Puijk WC, Kuperus D, Flinterman JF, Schaaper WMM, Oonk HB, Meloen RH. Detection of epitopes on follicle-stimulating hormone and FSH-antiserum-induced suppression of bioactivity of follicle-stimulating hormone and luteinizing hormone. J. Reprod. Immunol. 1996, 30, 133-149.
  19. Geysen HM, Meloen RH, Barteling SJ. Use of peptide-synthesis to probe viral-antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci., USA 1984, 81, 3998-4002.

Synthetic Immunogens/Antibody Generation:

  1. Barderas R, Shochat S, Timmerman P, Hollestelle MJ, Martínez-Torrecuadrada JL, Höppener JWM, Altschuh D, Meloen RH, Casal JI, Designing antibodies for the inhibition of gastrin activity in tumoral cell lines. Int. J. Canc. 2008, 122, 2351-2359.
  2. Barderas R, Desmet J, Timmerman P, Meloen RH, Casal JI, Affinity maturation of antibodies assisted by in silico modeling. Proc. Natl. Acad. Sci., USA 2008, 105, 9029-9034.
  3. Barderas R, Shochat S, Martínez-Torrecuadrada J, Altschuh D, Meloen RH, Casal JI. A fast mutagenesis procedure to recover soluble and functional scFvs containing amber stop codons from synthetic and semisynthetic antibody libraries. J. Immunol. Methods 2006, 312, 182-189.
  4. Scibelli A, van der Most RG, Turkstra JA, Ariaans MP, Arkesteijn G, Hensen EJ, Meloen RH. Fast track selection of immunogens for novel vaccines through visualisation of the early onset of the B-cell response. Vaccine 2005, 23, 1900-1909.
  5. Turkstra JA, van der Meer FJ, Knaap J, Rottier PJ, Teerds KJ, Colenbrander B, Meloen RH. Effects of GnRH immunization in sexually mature pony stallions. Anim. Reprod. Sci. 2005, 86, 247-59.
  6. Turkstra JA, Schaaper WM, Oonk HB, Meloen RH. GnRH tandem peptides for inducing an immunogenic response to GnRH-I without cross-reactivity to other GnRH isoforms. Vaccine 2005, 23, 4915-20.
  7. Turkstra JA, Oonk HB, Schaaper WMM, Meloen RH. The role of the individual amino acids of a GnRH-tandem-dimer peptide used as an antigen for immunocastration of male piglets determined with systematic alanine replacements. Vaccine 2002, 20, 406-412.
  8. Beekman NJCM, Schaaper WMM, Langeveld JPM, Boshuizen RS, Meloen RH. The nature of the bond between peptide and carrier molecule determines the immunogenicity of the construct. J. Pept. Res. 2001, 58, 237-245.
  9. Meloen RH, Langeveld JPM, Schaaper WMM, Slootstra JW. Synthetic peptide vaccines: unexpected fulfillment of discarded hope? Biologicals 2001, 29, 233-236.
  10. Beekman NJCM, Schaaper WMM, Turkstra JA, Meloen RH. Highly immunogenic and fully synthetic peptide-carrier constructs targetting GnRH. Vaccine 1999, 17, 2043-2050.
  11. Fernández IM, Golding H, Benaissa-Trouw BJ, de Vos NM, Harmsen M, Nottet HS, Golding B, Puijk WC, Meloen RH, Snippe H, Kraaijeveld CA. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV. Vaccine 1998, 16, 1936-1940.
  12. Oonk HB, Turkstra JA, Schaaper WMM, Erkens J, Schuitemaker-de Weerd MH, van Nes A, Verheijden JHM, Meloen RH. New GnRH-like peptide constructs to optimize efficient immunocastration of male pigs by immunoneutralization of GnRH. Vaccine 1998, 16, 1074-1082.
  13. Piccardo P, Langeveld JPM, Hill AF, Dlouhy SR, Young K, Giaccone G, Rossi G, Bugiani M, Bugiani O, Meloen RH, Colling J, Tagliavini F, Ghetti B. An antibody raised against a conserved sequence of the prion protein recognizes pathological isoforms in human and animal prion diseases, including Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Am. J. Pathol. 1998, 152, 1415-1420.
  14. Beekman NJCM, Schaaper WMM, Tesser GI, Dalsgaard K, Kamstrup S, Langeveld JPM, Boshuizen RS, Meloen RH. Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity. J. Pept. Res. 1997, 50, 357-364.

Bioactive/Therapeutic Peptides:

  1. Boshuizen RS, Schulz V, Morbin M, Mazzoleni G, Meloen RH, Langedijk JP. Heterologous stacking of prion protein peptides reveals structural details of fibrils and facilitates complete inhibition of fibril growth. J. Biol. Chem. 2009, 284, 12809-12820.
  2. Boshuizen RS, Morbin M, Mazzoleni G, Tagliavini F, Meloen RH, Langedijk JP. Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site. Amyloid – J. Prot. Fold. Dis. 2007, 14, 205-19.
  3. Thevissen K, François IE, Sijtsma L, van Amerongen A, Schaaper WM, Meloen RH, Posthuma-Trumpie T, Broekaert WF, Cammue BP. Antifungal activity of synthetic peptides derived from Impatiens balsamina antimicrobial peptides Ib-AMP1 and Ib-AMP4. Peptides 2005, 26, 1113-1119.
  4. Langedijk JP, Olijhoek T, Schut D, Autar R, Meloen RH. New transport peptides broaden the horizon of applications for peptidic pharmaceuticals. Mol. Divers. 2004, 8, 101-111.
  5. Boshuizen RS, Langeveld JP, Salmona M, Williams A, Meloen RH, Langedijk JP. An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Anal. Biochem. 2004, 333, 372-80.